[Induracin, prolonged-action nicotinic acid, in the treatment of atherogenic dyslipoproteinemia].
The author presents the results of a cross-over blind trial of induracin, prolonged nicotinic acid. The study covered 31 dyslipoproteinemic patients and lasted 6 months. The treatment gave rise to a significant fall in the total cholesterol, LDL cholesterol, triglycerides (by 11%, 17% and 19% respectively), HDL cholesterol levels went up by 14%, lipid transport proteins proportions changed for the better (AI apoprotein increased by 15% against lowering of apoprotein B by 29%). The drug was well tolerated.
Kiseleva
N G
NG
D000328:Adult; D000368:Aged; D016632:Apolipoprotein A-I / Q000187:drug effects; D001055:Apolipoproteins B / Q000187:drug effects; D002784:Cholesterol / Q000097:blood; D008076:Cholesterol, HDL / Q000187:drug effects; D008078:Cholesterol, LDL / Q000187:drug effects; D003131:Combined Modality Therapy; D003327:Coronary Disease / Q000150:complications; D018592:Cross-Over Studies; D003692:Delayed-Action Preparations; D004036:Diet, Atherogenic; D004311:Double-Blind Method; D005260:Female; D006801:Humans; D006938:Hyperlipoproteinemia Type II / Q000097:blood / Q000178:diet therapy / Q000188:drug therapy* / Q000209:etiology; D008297:Male; D008875:Middle Aged; D009525:Niacin / Q000494:pharmacology / Q000627:therapeutic use*; D016896:Treatment Outcome; D014280:Triglycerides / Q000097:blood
D016632:Apolipoprotein A-I; D001055:Apolipoproteins B; D008076:Cholesterol, HDL; D008078:Cholesterol, LDL; D003692:Delayed-Action Preparations; D014280:Triglycerides; D009525:Niacin; D002784:Cholesterol
Vozmozhnosti korrektsii aterogennykh dislipoproteidemiĭ induratsinom -- prolongirovannoĭ formoĭ nikotinovoĭ kisloty.